Associate Professor ANDREW PAUL BARBOUR

MBBS, PhD, FRACS
General Surgeon specialising in Upper GI, Melanoma and Soft Tissue
University of Queensland, School of Medicine
Discipline of Surgery

 

Qualifications

1988 – 1992

MBBS (Honours)
University of Queensland

2002

Doctor of Philosophy (PhD)
University of Queensland

2003

FRACS
Fellow Royal Australasian College of Surgeons

2010

FACS
Fellow American College of Surgeons

 

Medical Licensure

Queensland Medical Board
Annual Practising Certificate No. 940374

General Medical Council (United Kingdom)

New York Medical Board
Limited Permit to Practice Medicine

 

Distinctions & Awards

2012

James IV Association Travelling Fellow (2013)

2009

American College of Surgeons (ACS) International Scholarship

2002

Queensland Cancer Fund Travelling Scholarship

2001

American Association for Cancer Research Scholar in Cancer Research Award

2001

RACS Travelling Fellowship

2000

Princess Alexandra Hospital Society Travel Grant

1999-2000

NH&MRC Post-graduate Medical Research Scholarship

1999-2000

RACS Surgeon Scientist Fellowship

1998

Princess Alexandra Hospital Registrar’s Prize

 

Professional Memberships

Australia and New Zealand Gastro-Oesophageal Surgeons Association (ANZGOSA, Current)
Australia and New Zealand Hepato-Pancreatico-Biliary Association (ANZHPBA, Current)
International Society for Disease of the Esophagus (ISDE, Current)
Australian Sarcoma Group (ASG, current)
Australian Sarcoma Study Group (ASSG, Current)
Australian Melanoma Trials Group
American Association for Cancer Research
Australian Gastrointestinal Trials Group (AGITG, Current)
International Society of Gastric Cancer (Current)
Gastroenterological Society of Australia (Current)
Surgical Research Society of Australasia (Current)
Clinical Oncological Society of Australia (COSA, Current)
Gastroenterological Society of Queensland (GESA, Current)
Royal Australasian College of Surgeons (Current)
American College of Surgeons (ACS, Current)
Society of Surgical Oncology (SSO, Current)


Appointments

October 2005 – current

Senior Lecturer
University of Queensland, School of Medicine
Discipline of Surgery
Princess Alexandra Hospital Woolloongabba, QLD

October 2005 – current

Visiting Surgeon, Upper GI and Soft Tissue Unit
General Surgeon, Princess Alexandra Hospital
Woolloongabba, QLD

July 2004 – July 2005

Surgical Oncology Fellow
Memorial Sloan-Kettering Cancer Center
New York, New York, United States of America

August 2003 – June 2004

Upper GI Fellow
Department of Surgery, Bristol Royal Infirmary
Bristol, United Kingdom

January – August 2003

Staff Specialist, General Surgeon
Gold Coast Hospital
Southport, QLD

1997 – 2002

General Surgery Registrar
Princess Alexandra Hospital
Woolloongabba, QLD

1998 – 2000

PhD Scholar
Cellular Oncology Laboratory
Queensland Institute of Medical Research
Herston, QLD

1993 – 1996

House Officer Appointments
Queen Elizabeth II Hospital
Nathan, QLD

Nambour General Hospital
Nambour, QLD

Gold Coast Hospital
Southport, QLD

Mater Misericordiae Hospitals
Woolloongabba, QLD

 

Research

Throughout my career I have maintained a commitment to the academic aspects of surgical practice as well as clinical care of patients. My major research themes are Upper GI malignancy, melanoma and soft tissue sarcoma.  My academic interests have encompassed the areas of 1) clinical research, including randomised controlled clinical trials, 2) laboratory based research, including molecular biology pertinent to upper gastrointestinal disease and melanoma, 3) translational research integrating the laboratory and clinical domains.

As a clinical researcher, I have been active in the conduct of clinical trials at Phase I, II and III levels. This has culminated in the development of a randomised phase II trial of preoperative chemotherapy or chemo-radiotherapy based on poor early response to standard chemotherapy for resectable oesophageal cancer (DOCTOR trial, NHMRC APP #1011782) as CIA. I am also the principal investigator on an investigator initiated, AGITG-sponsored phase II clinical trial of pre-operative chemotherapy for pancreatic cancer (GAP trial). Both of these national trials include biological substudies with tumour tissue and blood banking and subsequent molecular analyses aimed at answering specific questions, including the identification of biomarkers of response to therapy. The GAP translational study (GAP-T) is funded by NHMRC (APP#1026563).

As a translational researcher at the School of Medicine, PAH, University of Queensland, I am the head of Surgical Oncology Lab at the School of Medicine. My research has focused on using genomic, epigenomic and expression data to classify oesophageal adenocarcinoma (OAC) and identify biomarkers of outcome (Cancer Council Queensland Project Grant #631544). We will be undertaking a comprehensive genomic study of OAC, including next generation sequencing, commencing in 2012 (APP#1021403). These studies are focussed on the large number of well curated tumour tissue bank OAC specimens with accompanying clinical data available at the PAH. As a result, I have expertise in the analysis of cancer using cDNA microarrays and SNP arrays.

 

Research Collaborations

2012

PROBE-NET: The Progression of Barrett's Esophagus to Cancer Network (NHMRC CRE $2,465,841, CIA Whiteman) This application brings together the seven major research teams in Australia with expertise in oesophageal cancer to form a multi-state, multi-disciplinary Centre of Research Excellence. All of the nodes have worked together collaboratively for the past 4 years, pooling their expertise in surgery, gastroenterology, endoscopy, epidemiology, biostatistics, basic science, health policy and translational research. The vision is to develop evidence-based strategies for reducing the burden of oesophageal neoplasia.

2010

AGITG Pre-operative response based chemotherapy trial for oesophageal cancer (DOCTOR trial, NHMRC #1011782)

2010

  1. AGITG Pre-operative Gemcitabine and Abraxane for resectable pancreas cancer trial (GAP trial).

2009

Human papilloma virus in squamous carcinoma of the oesophagus with Prof Raina MacIntyre, Professor Infectious Diseases Epidemiology and Head of School of Public Health and Community Medicine, The University of New South Wales.

2009

  1. Collaboration with Dr David Whiteman, Dr Derek Nancarrow and Dr Nick Hayward (QIMR) to investigate genome-wide analyses for the identification of biomarkers in oesophageal adenocarcinoma.

2008

Developing a partnership with Sanofi-Aventis for clinical trial

2008

Dr Peter O’Rourke& David Whiteman at QIMR “Oesophageal cancer outcomes”

2008

Clinical investigator as part of collaboration with QIMR and multiple Australian clinical centres for STREP grant “Progression of Barrett’s Oesophagus to Cancer”.

2007

Research collaboration with Medical and Radiation Oncology at the PAH in clinical trials development.

2006

Collaboration with Dr Itzak Avital, National Institutes of Health, Bethesda, MD, USA.

 

Research Grants & Contracts

2013-2018 PROBE-NET: The Progression of Barrett's Esophagus to Cancer Network. CIA Whiteman, Phillips, Lord, Hayward, Watson, Barbour, Bourke, Eslick, Penman. NHMRC CRE $2,465,841

2012-2014 Whole genome analyses of oesophageal adenocarcinoma. CIA Barbour, Waddell, Krause, Nancarrow, Hussey, Watson, Lord. $957,987

2012-2014 Personalising care in operable pancreas cancer. A study of imaging and molecular biomarkers to guide treatment of patients receiving preoperative chemotherapy followed by surgery. Application ID 1026563. Chief Investigators: CIA Barbour, Goldstein, Kench, Chang, Yip, Brown. $391,987

2011-5 DOCetaxel with or without radiation Therapy for resectable Oesophageal adenocarcinoma based on early PET Response to induction chemotherapy (DOCTOR). NH&MRC. Application ID 1011782. Chief Investigators: CIA Barbour, Smithers, Burmeister, Walpole, Zalcberg, Spry, Smith $791,991.42

2010-11 Genome-wide analysis of oesophageal cancer: towards biomarkers of response and outcomes of therapy. The Cancer Council Queensland. Application ID 631544. Chief Investigators: CIA Barbour, Nancarrow, Smithers, Gotley. $167,000.00

2011

Biomarkers for Stage III Melanoma Recurrence and Response to Radiotherapy.
Grant from PA Hospital Foundation ($70 000)
Chief Investigator

2009

Genome-wide analyses of oesophageal cancer
Grant from CCG, PA Hospital
Chief Investigator

2008

Pancreatic cystic lesion database
Grant from Gallipoli Research Foundation
Chief Investigator

2007

Identification and Characterisation of Cancer Stem Cells in Gastric Cancer
Grant from CICR, PA Hospital and University of Queensland
Chief Investigator

2007

Pancreatic cystic lesion database
Grant from Gallipoli Research Foundation
Chief Investigator

2003 – 2005

Mechanisms of CD44-mediated metastasis (252863)
Grant from NHMRC

2003 – 2005

CD44 as a target for metastasis therapy (252864)
Grant from NHMRC

 

Teaching

I continue to be involved in teaching students involved in the MBBS program within my 0.4 FTE appointment. This predominately relates to those in the second (MEDI2006) to third years (MEDI3003).  I have been System Leader for the gastrointestinal and musculoskeletal systems for years one and two.  I have been responsible for the teaching of a group of third year medical students for each surgical rotation at the PA Hospital.  I remain committed to teaching students and attending the examination sessions.

I am closely involved in the teaching and guidance of FRACS advanced surgical trainees and with Surgeons working as fellows / senior registrars at the Princess Alexandra Hospital.  The teaching occurs formally in sessions and informally in the clinics and the operating theatre.  I am also strongly committed to mentoring both medical student and junior medical staff.  I have arranged formal sessions in career development with the surgical trainees, specifically directed at encouraging academic surgery.

I have proposed and implemented changes to the post graduate teaching program at Princess Alexandra Hospital that emphasizes the interpretation of available evidence, its application to a specific case and presentation skills.

I am frequently asked to give lectures to surgical and medical groups dealing with areas of my expertise.  I am requested to give lectures at General Practice education evenings in Brisbane.  In addition I have been an invited speaker at major skin cancer conferences and have provided Melanoma education for the Cancer Council Queensland (TCCQ) Volunteers.

 

Publications & Presentations

 

Publications

Barbour, A., Reeder, J., Walsh, M., Fawcett, J., Antalis, T., and Gotley, D. (2003) Expression of the CD44v2-10 isoform confers a metastatic phenotype: importance of the heparan sulfate growth factor binding domain CD44v3. Cancer Research 63, 887-892.

Barbour, A. and Gotley, D. (2003) Current concepts of tumour metastasis. Ann Acad Med Singapore 32,176-84.

Barbour AP, Lagergren P, Hughes R, Alderson D, Barham CP, Blazeby JM. Health-related quality of life among patients with adenocarcinoma of the gastro-oesophageal junction treated by gastrectomy or oesophagectomy. Br J Surg. 2008 Jan;95(1):80-4.

Barbour AP, Rizk NP, Gerdes H, Bains MS, Rusch VW, Brennan MF, Coit DG. Endoscopic Ultrasound Predicts Outcomes for Patients with Adenocarcinoma of the Gastroesophageal Junction. J Am Coll Surg. 2007 Oct;205(4):593-601.

Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg. 2007 Jul;246(1):1-8.

Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF. Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome. Ann Surg Oncol. 2007 Feb;14(2):306-16

Smithers BM, Cullinan M, Thomas JM, Martin I, Barbour AP, Burmeister BH, Harvey J, Thomson DB, Walpole E, Gotley DC. Outcomes from salvage esophagectomy post definitive chemoradiotherapy compared with resection following preoperative neoadjuvant chemoradiotherapy. Dis Esophagus 2007;20(6):471-7.

Barbour, A., Gotley, D., Thomas, J., Martin, I., Walpole, E., Thompson, D., Harvey, J., Burmeister, B., Smithers, B.M. Refining Oesophageal Cancer Staging After Neoadjuvant Therapy: Importance of Primary Tumour Response. Ann Surg Oncol. 2008;15(10):2894-902.

Shenfine J, Barbour AP, Wong D, Thomas J, Martin I, Gotley DC, Smithers BM. Prognostic value of maximum standardized uptake values from preoperative positron emission tomography in resectable adenocarcinoma of the esophagus treated by surgery alone. Dis Esophagus. 2009;22:668-75.

Barbour AP, Thomas J, Suffolk J, Beller E, Smithers BM.Isolated Limb Infusion for Malignant Melanoma: Predictors of Response and Outcome. Ann Surg Oncol. 2009;16:3463-72.
Thomson IG, Smithers BM, Gotley DC, Martin I, Thomas JM, O'Rourke P, Barbour AP. Thoracoscopic-assisted esophagectomy for esophageal cancer: analysis of patterns and prognostic factors for recurrence. Ann Surg. 2010;252:281-91

Barbour AP, Jones M, Brown I, Gotley DC, Martin I, Thomas J, Clouston A, Mark Smithers B. Risk stratification for early esophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors. Ann Surg Oncol. 2010;17:2494-502.

Burmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, Barbour AP, Gotley DC, Smithers BM. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011 Feb;47(3):354-60.

Thomson IG, Smithers BM, Gotley DC, Martin I, Thomas JM, O'Rourke P, Barbour AP. Thoracoscopic-assisted esophagectomy for esophageal cancer: analysis of patterns and prognostic factors for recurrence. Ann Surg. 2010 Aug;252(2):281-91.

Hirst J, Smithers BM, Gotley DC, Thomas J, Barbour A. Defining Cure for Esophageal Cancer: Analysis of Actual 5-Year Survivors Following Esophagectomy. Ann Surg Oncol. 2011 Jun;18(6):1766-74.

Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V; for the Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011 Jul;12(7):681-692.

Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS. Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors. Gastroenterology. 2012;142(4):1021-1031.

Gordon LG, Hirst NG, Mayne GC, Watson DI, Bright T, Cai W, Barbour AP, Smithers BM, Whiteman DC, Eckermann S; Australian Cancer Study Clinical Follow-Up Study. Modeling the Cost-effectiveness of Strategies for Treating Esophageal Adenocarcinoma and High-grade Dysplasia. J Gastrointest Surg. 2012;16(8):1451-61.

Foote M, Burmeister B, Dwyer P, Burmeister E, Lambie D, Allan C, Barbour A, Bayley G, Pullar A, Meakin J, Thomas J, Smithers M. An innovative approach for locally advanced stage III cutaneous melanoma: radiotherapy, followed by nodal dissection. Melanoma Res. 2012;22(3):257-62.

Frankel A, Nancarrow D, Wayte N, Barbour A. Clinical issues in oesophageal adenocarcinoma: could DNA copy number hold the key? ANZ J Surg. 2012 Aug 1.

Liyanage SS, Segelov E, Garland SM, Tabrizi SN, Seale H, Crowe PJ, Dwyer DE, Barbour A, Newall AT, Malik A, Macintyre CR. Role of human papillomaviruses in esophageal squamous cell carcinoma. Asia Pac J Clin Oncol. 2012 Aug 9.

Gordon LG, Hirst NG, Mayne GC, Watson DI, Bright T, Cai W, Barbour AP, Smithers BM, Whiteman DC, Eckermann S. Modeling the cost-effectiveness of strategies for treating esophageal adenocarcinoma and high-grade dysplasia. J Gastrointest Surg. 2012 Aug;16(8):1451-61

Biankin A, Waddell N, Kassahn K, Gingras M, Muthuswamy B, Johns A, Miller D, Wilson P, Patch A, Wu J, Chang D, Cowley M, Gardiner B, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning M, Wani S, Gongora M, Pajic M, Scarlett C, Gill A, Pinho A, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu C, Nones K, Fink L, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead R, Humphris J, Kaplan W, Jones M, Colvin E, Nagrial A, Humphrey E, Chou A, Chin V, Chantrill L, Samra J, Kench J, Lovell J, Daly R, Merrett N, Toon C, Epari K, Nguyen N, Barbour A, Zeps N, Australian Pancreatic Cancer Genome Initiative, Kakkar n, Zhao F, et al. Genomic Analysis Reveals Aberrations in Chromatin Modification and Axon Guidance Pathway Genes in Pancreatic Cancer. Nature (in press).

Hii MW, Smithers BM, Gotley DC, Thomas JM, Thomson I, Martin I, Barbour AP. Impact of postoperative morbidity on long-term survival after oesophagectomy. Br J Surg. 2013;100(1):95-104.

Invited Review Articles

Cameron A, Barbour A, Wayte N, Akhurst, T. Biomarkers in oesophagogastric cancers. Cancer Forum. 2011;35(3): 160-166.
Geere S and Barbour AP. Management of loco-regionally recurrent melanoma (Manuscript in preparation for Cancer Forum)

NH&MRC Melanoma guidelines: Appropriate use of investigations chapter and Follow up chapter
These are the national guidelines for the treatment of melanoma for general practitioners and specialist medical practitioners. The guidelines have been reviewed and commended by the NIH melanoma group.

 

Invited Presentations

Barbour, A. Adjuvant Therapy and Gastro-oesophageal Cancer: The Surgeon’s Dilemma! Clinical Oncology Society of Australia, Annual Meeting, Brisbane, Australia.

Barbour, A. The role of Endoscopic Ultrasound and Adequate Staging for Patients with Adenocarcinoma of the Gastro-Oesophageal Junction. Australian Gastrointestinal Trials Group, Annual Meeting, Brisbane, Australia.

Barbour, A., Rizk, N., Gerdes, H., Bains, M., Rusch, V., Brennan, M., and Coit, D. (2005) Endoscopic Ultrasound (EUS) Predicts Outcome for Patients with Adenocarcinoma of the Gastro-Esophageal Junction (GEJ). Proceedings of the 6th International Gastric Cancer Congress, Yokohama, Japan.

Chairperson, Oral Presentation Session “Staging of Gastric Cancer”, 6th International Gastric Cancer Congress, Yokohama, Japan.

 

Abstracts

Barbour A, Smithers B, Burmeister B, Zalcberg J, Spry N, Smith G, Wilson K, Roff K, Yip S, Walpole E. DOCTOR: A Randomised Phase II Trial of Pre-operative cisplatin, 5 fluorouracil and docetaxel ± Radiotherapy based on poor early response to standard chemotherapy for resectable adenocarcinoma of the oesophagus and/or OG Junction. (2012) ASCO Annual Scientific Meeting, Chicago, USA. 

Nicola Wayte, Derek Nancarrow, David Gotley, Euan Walpole, Guy Lampe, Bernard Smithers, Andrew Barbour. (2012) Gene expression analysis of EAC in association with PET response. ASCO GI Symposium, San Diego, USA.

Andrew Hughes, David C. Gotley, Janine Thomas, Pathologist, B. Mark Smithers, Andrew P. Barbour. (2007) Surgery for early esophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors. Ann Surg Oncol 2 (supp): 103 (P237).

Barbour, A., Gotley, D., Thomas, J., Martin, I., Walpole, E., Thompson, D., Harvey, J., Burmeister, B., Smithers, B.M. (2006) Patterns and Predictors of Initial Recurrence Following Resection for Adenocarcinoma of the Oesophagus and Gastro-Oesophageal Junction (GOJ). Proceedings Annual Scientific Meeting, Royal Australasian College of Surgeons, Sydney Australia.

Barbour, A., Gotley, D., Thomas, J., Martin, I., Walpole, E., Thompson, D., Harvey, J., Burmeister, B., Smithers, B.M. (2006) Refining Oesophageal Cancer Staging After Neoadjuvant Therapy:
Importance of Primary Tumour Response. Proceedings Annual Scientific Meeting, Royal Australasian College of Surgeons, Sydney Australia.

Barbour, A., Thomas, J., Suffolk, J., Beller, E., Smithers, B.M. (2006) Isolated Limb Infusion (ILI) for Malignant Melanoma: Predictors of Response and Outcome. Proceedings Annual Scientific Meeting, Royal Australasian College of Surgeons, Sydney Australia.

Barbour, A., Thomas, J., Suffolk, J., Beller, E., Smithers, B.M. (2006) Isolated Limb Infusion (ILI) for Malignant Melanoma: Predictors of Response and Outcome. Proceedings Annual Scientific Meeting, Royal Australasian College of Surgeons, Sydney Australia.

Barbour, A., Thomas, J., Suffolk, J., Beller, E., Smithers, B.M. (2006) Isolated Limb Infusion (ILI) for Malignant Melanoma: Predictors of Response and Outcome. Ann Surg Onc. 13 (suppl), P60.

Barbour, A., Rizk, N., Gonen, M.,  Bains, M., Rusch, V., Coit, D., and Brennan, M. (2006) Lymphadenectomy for Adenocarcinoma of the Gastroesophageal Junction (GEJ): Analysis of the Impact on Prognostic Factors and Outcome. Ann Surg Onc. 13 (suppl), A76.

Barbour, A., Moorghen, M., Barham, C.P., Blazeby, J.M., and Alderson, D. (2006) Microscopic positive margins confer poor prognosis in patients with oesophageal cancer following potentially curative resection. Proceedings International Society for Diseases of the Esophagus, Adelaide, Australia.

Barbour, A., Moorghen, M., Barham, C.P., Blazeby, J.M., and Alderson, D. (2006) Endoscopic Ultrasound Predicts Outcome for Patients with Oesophageal Cancer. Proceedings International Society for Diseases of the Esophagus, Adelaide, Australia.

Barbour, A., Barham, C.P., Vickers, J., Armstrong, C.P., Alderson, D., and Blazeby, J.M.. (2005) A comparison of patient-based outcomes for total gastrectomy and oesophagectomy as curative treatment for junctional adenocarcinoma. Proceedings Association of Surgeons of Great Britain and Ireland, Harrogate, England.

Barbour, A., Reeder, J., Antalis, T., Walsh, M., Fawcett, J. and Gotley, D. (2001) CD44v2-10 promotes metastasis in human hepatocellular carcinoma cells independent of hyaluronan binding. Proceedings of the American Association for Cancer Research. 42, 916, #4918.

 

Editorial Appointments

I am a reviewer for the British Journal of Surgery, Annals of Surgical Oncology, BMC Cancer, the Australia and New Zealand Journal of Surgery and Diseases of the Esophagus.

Committee member for the development of new NH&MRC guidelines for the management of malignant melanoma.

 

Professional Service Activities

2012

Cancer Australia
Grant Review Committee Member

2009

Australasian Gastrointestinal Trials Group
Chairman, Surgical sub-committee for Annual Scientific Meeting

2009

Australasian Gastrointestinal Trials Group
Member, Scientific Advisory Committee

2009

Queensland Cooperative Oncology Group (2009)
Executive Member

2009

RACS
Convenor of Surgical Oncology Program for RACS ASC

2008 -

GESA (2008-current)

2008

RACS
Co-convenor Surgical Oncology
Conference

2007 -

RACS
SET Program Interviewer